Long-Term Effect of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Injections in Choroidal Neovascularization Secondary to Angioid Streaks

Table 1

Demographic and baseline characteristics of patients with choroidal neovascularization secondary to angioid streaks.

	Mean ± std. deviation (relative frequency)
No. of patients included	29
No. of eyes included	39
Female	17 (58.6%)
Age (years)	53.0 ± 12.3
Both eyes affected	10 (34.5%)
PEX	15 (51.7%)
Age in PEX patients (years)	49.0 ± 10.5
PDT (eyes)	5 (12.8%)
CNV location
Subfoveal	13 (33.3%)
Juxtafoveal	22 (56.4%)
Extrafoveal	4 (10.3%)
Baseline BCVA (ETDRS letters)	59.3 ± 23.3
Baseline CMT (µm)	343.3 ± 120.0
Follow-up (months) (minimum-maximum)	69.4 ± 34.5 [36–135]

BCVA: best-corrected visual acuity, CMT: central macular thickness, CNV: choroidal neovascularization, ETDRS: Early Treatment Diabetic Retinopathy Study, PDT: photodynamic therapy, PEX: pseudoxanthoma elasticum.